Genetic inhibition of complement mediated inflammatory response

Details Genetic inhibition of complement mediated inflammatory response Genetic inhibition of complement mediated inflammatory response

1996-08-13

1999-09-21

Stanton, Brian R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

A01N 4304

Patent

active

059554410

ABSTRACT:
A method and means for protecting cells and transplanted organs from the effects of activated complement proteins generated in blood serum or plasma by introducing the gene for CD59 into the cells to be protected is described. In an example of the method, protection against the pore-forming activity of the human C5b-9 proteins was conferred on CHO cells by transfection with cDNA encoding the human complement regulatory protein CD59.

REFERENCES:
Walsh et al. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur. J. of Immun., vol. 21, No. 3, pp. 847-850, Mar. 1991.
Weatherall, D J. Scope and limitations of gene therapy. British Medical Bulletin, vol. 51, No. 1, pp. 1-11, 1995.
NIH panel. Report and recommendations of the Panel to Assess the NIH investment in research on gene therapy, Dec. 07, 1995.

Affiliated with

Also associated with

Rating

Genetic inhibition of complement mediated inflammatory response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genetic inhibition of complement mediated inflammatory response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic inhibition of complement mediated inflammatory response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-80315